Catalent Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 02:45PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst

Everybody. Luke Sergott here at Barclays to cover Life Sciences Tools and Diagnostics. With me, I have Paul Surdez, VP, Investor Relations; and Tom Castellano, CFO of Catalent. So we're already 45 seconds behind schedule, so I guess we could jump right into the questions here.

Questions and Answers:

Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst

You made a comment on the last quarter, where you were talking about revisiting your rev rec policy and how that's going to impact the rest of the business. Talk about really the genesis of that comment, and how the business has changed and why you would need to reconsider?

Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO

Yes, sure. So thanks, everyone, for having me, Luke, here, and I appreciate the question.

So the question around revenue recognition was really tied specifically to the relationship that Catalent has with Sarepta and their
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot